Progentec strategic collaboration
Predicting disease progression
The DX Lupus Flare Risk Index uses advanced algorithms and biomarkers to forecast flare risk within 12 weeks, enabling timely interventions.
Enhancing clinical decision-making
The DX Lupus Disease Activity Index provides a clear picture of current disease activity, guiding treatment adjustments and care frequency.
Innovating for patient well-being
Through this strategic collaboration, we deliver cutting-edge tools that empower clinicians to improve the quality of life for patients living with lupus.
“These tests represent a significant step forward in lupus care, giving physicians tools to anticipate flares and tailor treatment plans for better patient outcomes.”
William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories
The latest
New ACR lupus guidelines highlight the vital role of lab testing in monitoring disease and guiding treatment decisions.
The following cases are designed for healthcare professionals interested in understanding the assessment and treatment options for patients with systemic lupus erythematosus disease.
The Lupus Foundation of America estimates that at least five million people worldwide have a form of lupus. Yet, the most widely used laboratory tests for patients with this complex condition were developed more than 60 years ago, and physicians need modern, evidence-based tools to provide high-quality care for their patients. That is why Mayo Clinic Laboratories and Progentec Diagnostics joined forces to provide solutions that transform that experience.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.